Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

NL0015002SN0
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000GTYWL7
QGEN
Qiagen NV
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical - Diagnostics & Research
NAME
Qiagen NV
ISIN
NL0015002SN0
TICKER
QGEN
MIC
XNYS
REUTERS
QGEN.N
BLOOMBERG
QGEN US
Mon, 27.01.2025       Qiagen
NL0015001WM6

Das Instrument QIA NL0015001WM6 QIAGEN NV EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 28.01.2025 und ex Kapitalmassnahme am 29.01.2025 The instrument QIA NL0015001WM6 QIAGEN NV EO -,01 EQUITY is traded cum capital adjustment on 28.01.2025 and ex capital adjustment on 29.01.2025...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.01.2025       Qiagen
NL0015001WM6

Das Instrument QIA NL0015001WM6 QIAGEN NV EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 28.01.2025 und ex Kapitalmassnahme am 29.01.2025 The instrument QIA NL0015001WM6 QIAGEN NV EO -,01 EQUITY is traded cum capital adjustment on 28.01.2025 and ex capital adjustment on 29.01.2025...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.01.2025       Qiagen
NL0015001WM6

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. QIAGEN announced earlier in January plans for the repurchase, which comes afte...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.01.2025       Qiagen
NL0015001WM6

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time /...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.01.2025       Qiagen
NL0015001WM6

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. This new repurchase comes after QIAGEN returned approximately $300 millio...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.01.2025       Qiagen
NL0015001WM6

Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück Venlo, Niederlande, 12. Januar 2025 – QIAGEN N.V. gibt Pläne bekannt, mittels eines synthetischen Aktienrückkaufs bis zu rund $300 Mio. (maximal EUR 281 Mio.) an Akt......
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.01.2025       Qiagen
NL0015001WM6

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase Venlo, the Netherlands, January 12, 2025 – QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share rep......
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.01.2025       Qiagen
NL0015001WM6

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample. The new capabilities overcome the assay design challenges...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.01.2025       Qiagen
NL0015001WM6

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by the U.S. Food and Drug Administration (FDA) marks the second mini syndromic panel in the U.S. and made available for use with QIAstat-Dx systems,...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.01.2025       Qiagen
NL0015001WM6

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study. This first-of-its-kind initiative aims to sequence the genomes of 100,000 newborns in England to screen for over 200 selected conditions, enabling earlier diagnosis and treatment of rare...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 12.12.2024       Qiagen
NL0015001WM6

QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, help...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.12.2024       Qiagen
NL0015001WM6

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated sample preparation instrument, an advancement of the EZ1 instrument line. Launched in 2021, the updated EZ2 Connect has quickly become a market-leading instrument for sample preparation...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.11.2024       Qiagen
NL0015001WM6

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.11.2024       Qiagen
NL0015001WM6

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.11.2024       Qiagen
NL0015001WM6

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastroint...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.10.2024       Qiagen
NL0015001WM6

Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research // New QIAsymphony DSP Circulating DNA and Maxi Kits del...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.10.2024       Qiagen
NL0015001WM6

QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission // Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies // CPD- and CME-accredited event highl...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.09.2024       Qiagen
NL0015001WM6

Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise monitoring of low-abundance targets in clinical diagnostics // Enhances lab efficiency and reduces costs with all-in-one instrument for either IVD assay...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.09.2024       Qiagen
NL0015001WM6

Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s devices meet the stringent safety, quality and performance standards for in-vitro diagnostics in Europe // QIAGEN on track to trans...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.09.2024       Qiagen
NL0015001WM6

PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 23.09.2024       Qiagen
NL0015001WM6

QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide // P...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.09.2024       Qiagen
NL0015001WM6

QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations // Portfolio expansion and...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.09.2024       Qiagen
NL0015001WM6

QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s Disease // Collaboration set to launch the first commercially available IVD Kit for APOE genotyping QIAGEN to develop the first QIAstat-D...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.09.2024       Qiagen
NL0015001WM6

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   Ad-hoc-Mitteilung nac......
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.09.2024       Qiagen
NL0015001WM6

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   Ad-hoc announcement p......
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.07.2024       Qiagen
NL0015001WM6

Partnership with University of Montana drives the implementation of next-generation sequencing and forensic investigative genetic genealogy in identifying human remains // QIAGEN provides instruments, kits and training for building the first Indigenous-owned DNA database and identifying African American human remains // Collaboration underlines QIA...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.07.2024       Qiagen
NL0015001WM6

Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024....
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.06.2024       Qiagen
NL0015001WM6

American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection American Academy of...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.06.2024       Qiagen
NL0015001WM6

Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing la...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.06.2024       Qiagen
NL0015001WM6

ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage // Social: // Leveraging partnerships, QIAGEN broadens diagnostic access worldw...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.06.2024       Qiagen
NL0015001WM6

35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.06.2024       Qiagen
NL0015001WM6

NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 mil...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.06.2024       Qiagen
NL0015001WM6

New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers’ customization needs, complementing QIAGEN’s existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.06.2024       Qiagen
NL0015001WM6

U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Pa...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.05.2024       Qiagen
NL0015001WM6

QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a...
Read more
Qiagen
Technical Analysis Termsheets Terminal
Permalink